| dbo:abstract
|
- Horizon Therapeutics Public Ltd Co is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. Horizon's drug portfolio is focused on treatments for thyroid eye disease (TED), gout, rare diseases, and inflammatory diseases. Horizon's portfolio includes Tepezza (teprotumumab), Krystexxa (pegloticase), Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), Rayos/Lodotra (prednisone), Vimovo (naproxen/esomeprazole magnesium), Buphenyl (sodium phenylbutyrate), Procysbi (cysteamine bitartrate), and Ravicti (glycerol phenylbutyrate). In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). (en)
- Horizon Therapeutics Public Limited Company (anciennement Horizon Pharma) est une entreprise pharmaceutique ayant ses principales activités aux États-Unis mais dont le siège social est en Irlande. Ses principaux produits sont liés au domaine de la douleur, de l'inflammation et de l'arthrite. (fr)
- Horizon Therapeutics — международная фармацевтическая компания. Номинальная штаб-квартира расположена в Дублине (Ирландия), фактический центр операций в Чикаго (США). Специализируется на препаратах для лечения редких заболеваний. (ru)
|
| dbo:foundingYear
| |
| dbo:headquarter
| |
| dbo:industry
| |
| dbo:keyPerson
| |
| dbo:netIncome
| |
| dbo:numberOfEmployees
|
- 1800 (xsd:nonNegativeInteger)
|
| dbo:revenue
| |
| dbo:thumbnail
| |
| dbo:type
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 12061 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:hqLocation
|
- * Dublin, Ireland
* Lake Forest , Illinois, USA (en)
|
| dbp:industry
| |
| dbp:isin
| |
| dbp:keyPeople
|
- Andy Pasternak (en)
- Jeffrey W. Sherman, M.D. (en)
- Paul W. Hoelscher (en)
- Timothy P. Walbert (en)
|
| dbp:logo
|
- File:Horizon Therapeutics logo.svg (en)
|
| dbp:name
|
- Horizon Therapeutics plc (en)
|
| dbp:netIncome
| |
| dbp:numEmployees
| |
| dbp:predecessor
| |
| dbp:revenue
| |
| dbp:type
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Horizon Therapeutics Public Limited Company (anciennement Horizon Pharma) est une entreprise pharmaceutique ayant ses principales activités aux États-Unis mais dont le siège social est en Irlande. Ses principaux produits sont liés au domaine de la douleur, de l'inflammation et de l'arthrite. (fr)
- Horizon Therapeutics — международная фармацевтическая компания. Номинальная штаб-квартира расположена в Дублине (Ирландия), фактический центр операций в Чикаго (США). Специализируется на препаратах для лечения редких заболеваний. (ru)
- Horizon Therapeutics Public Ltd Co is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (en)
|
| rdfs:label
|
- Horizon Therapeutics (fr)
- Horizon Therapeutics (en)
- Horizon Therapeutics (ru)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
|
- Horizon Therapeutics plc (en)
|
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
